Top Markets
Coin of the day
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Kedudukan dalam Saham #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Harga Saham
$0.5275
Modal Pasaran
$1.25M
Perubahan (1 hari)
-3.56%
Perubahan (1 tahun)
-83.77%
Negara
US
Perdagangan Ensysce Biosciences, Inc. (ENSC)

Kategori

Sejarah hasil dividen untuk Ensysce Biosciences, Inc. (ENSC)
Hasil dividen (TTM) bagi Ensysce Biosciences, Inc. (simbol saham: ENSC) pada 2023-12-31 adalah: 0.00%
Purata hasil dividen 5 tahun terakhir: 11,707.83%
Sejarah hasil dividen untuk Ensysce Biosciences, Inc. (ENSC) dari 2017 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
2026 (TTM) 0.00% -100.00%
2024 2,039.30% 0.00%
2023 0.00% -100.00%
2022 3.76% -99.99%
2021 56,496.11% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Hasil dividen (TTM) untuk syarikat serupa atau pesaing